Pharmacokinetic Clinical Trial
Official title:
An Open, One-sequence, Three-period Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Oral Single Dosing of Two Different Solid Formulations of GS-248
The study will collect information about pharmacokinetics (PK), safety and tolerability following a single dose of GS-248 in two different oral solid formulations in capsules to healthy subjects. It will also collect information about pharmacokinetics (PK), safety and tolerability following a single dose of one of the two formulations of GS-248 in fed condition.
The study is divided in two parts. Part I will evaluate PK, safety and tolerability of a single oral dose of two different formulations of GS-248 in fasting conditions. Part II will evaluate PK, safety and tolerability of one of the two different formulations of GS-248 in fed conditions. In Part I, a single oral dose of GS-248 in two different solid formulations will be administered to 14 healthy subjects. All subjects will first receive Formulation A and then Formulation B. A wash-out period of at least 4 days will be applied between the IMP administrations. Both doses contain 120 mg GS 248. For Part I, subjects will come to the clinic for single dose administration of Formulation A or Formulation B, respectively, and PK and safety assessments. Safety assessments include AE reporting, physical examination, ECG, vital signs, body temperature, and blood sampling for analysis of safety laboratory parameters. After evaluation of the PK profiles of Formulation A and B in Part I of the study, one formulation will be selected to be given following intake of a standardised breakfast in Part II of the study. Subjects will return to the clinic for a second dose of the selected formulation, yet now in fed conditions. The assessments during fed conditions will be the same as during fasting conditions except that the subjects will consume a high-fat high-calorie breakfast 30 minutes prior to IMP administration. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04531150 -
Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects
|
Phase 1 | |
| Completed |
NCT03437265 -
A Pharmacokinetic Study of PLENVU® in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT03979989 -
Drug-drug Interaction Study to Evaluate the Effect of Omeprazole on CG5503 (Tapentadol)
|
Phase 1 | |
| Completed |
NCT00743912 -
Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Healthy Volunteers
|
Phase 1 | |
| Not yet recruiting |
NCT05367011 -
Therapeutic Monitoring of Antibiotics in Intensive Care Patients: a Cohort Study PopTDM-ICU
|
||
| Completed |
NCT06126562 -
A Pharmacokinetic Study of Lanifibranor in Healthy Adult Chinese Subjects
|
Phase 1 | |
| Completed |
NCT00745264 -
Multi-Centre, Open-Label, Two Segment, Study Comparing Plasma Pharmacokinetics of Ketoprofen in Diractin® Alone to Diractin® Applied Concomitant With Heat or Moderate Exercise
|
Phase 1 | |
| Completed |
NCT03344627 -
Clinical Outcome Study of High-dose Meropenem in Sepsis and Septic Shock Patients
|
N/A | |
| Completed |
NCT01082796 -
Cytochrome P450 2C19 Variant is Related to Pharmacokinetics of Glipizide Extended Release Tablet in Chinese Subjects
|
N/A | |
| Terminated |
NCT02696954 -
Study of Artemether-lumefantrine, Amodiaquine and Primaquine in Healthy Subjects
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03714568 -
Pharmacokinetic and Tolerance Study of TQ-A3326 in Healthy Participants.
|
Phase 1 | |
| Recruiting |
NCT04080895 -
Pharmacokinetic Study of Artemether-lumefantrine and Amodiaquine in Healthy Subjects
|
Phase 1 | |
| Active, not recruiting |
NCT04735913 -
Effects of Metabolic Enzymes and Transporter Gene Polymorphisms on the Pharmacokinetics and Metabolism of Oral Abiraterone Acetate in Healthy Chinese Adults
|
Early Phase 1 | |
| Completed |
NCT03011996 -
To Investigate PK and PD of CJ-12420, Clarithromycin, Amoxicillin After Multiple Dose Administration
|
Phase 1 | |
| Completed |
NCT00681395 -
Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium
|
Phase 1 | |
| Not yet recruiting |
NCT06344858 -
Characterization of the Temporal Profile of the Anti-nociceptive Effect of Ketamine Bolus Measured With ANI
|
||
| Terminated |
NCT03059511 -
Pharmacokinetics of Nalbuphine After Intravenous and Intranasal Administration in Infants
|
Phase 1 | |
| Not yet recruiting |
NCT05938608 -
A Study to Assess the Availability of Oral Primaquine and Its Inert Metabolite, Carboxyprimaquine, in the Body
|
Phase 1 | |
| Completed |
NCT01091532 -
A Study In Healthy People Of Multiple Doses Of UK-396,082 Given By Mouth, To Investigate The Safety, Toleration And Time Course Of Blood Concentration Of UK-396,082 And Its Effects.
|
Phase 1 | |
| Completed |
NCT03951402 -
Effect of a Multiple-dose Oral Administration of CG5503 PR on the Electrical Activity of the Heart in 48 Healthy Men and Women
|
Phase 1 |